# AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

> **NCT06063850** · PHASE1,PHASE2 · RECRUITING · sponsor: **UniQure Biopharma B.V.** · enrollment: 12 (estimated)

## Conditions studied

- Mesial Temporal Lobe Epilepsy

## Interventions

- **GENETIC:** AAV9-hSyn1-miGRIK2

## Key facts

- **NCT ID:** NCT06063850
- **Lead sponsor:** UniQure Biopharma B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-12
- **Primary completion:** 2026-11-30
- **Final completion:** 2031-12
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06063850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06063850, "AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06063850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*